$XBI $137.03 +1%
Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$CYDN +18% New protocol discussed with FDA, specifically to duplicate or surpass the 82% survival rate over placebo. source
Pipeline Updates
$GILD +3% Submits BLA for Tecartus. source
$KDMN +2% Ph 2 initiated. source
$RLMD +4% Initiates ph 3 study of REL-1017. source
$PASG -3% Ph 1/2 study initiated. source
$UTHR +15% FDA approval of Tyvaso for PH-ILD. source
Finance Updates
$ELOX -7% acquires Zikani Therapeutics. source
$AGIO +2% Closes on sale of oncology portfolio. source
$FBIO +9% partner acquired QBREXZA from Dermira $LLY. source